• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
GU Xiaoke, TANG Xiaobo, HUANG Zhangjian, PENG Hui, ZHANG Yihua. Synthesis and antitumor activity of NO-releasing alkoxylbiphenyl derivatives[J]. Journal of China Pharmaceutical University, 2014, 45(6): 657-661. DOI: 10.11665/j.issn.1000-5048.20140606
Citation: GU Xiaoke, TANG Xiaobo, HUANG Zhangjian, PENG Hui, ZHANG Yihua. Synthesis and antitumor activity of NO-releasing alkoxylbiphenyl derivatives[J]. Journal of China Pharmaceutical University, 2014, 45(6): 657-661. DOI: 10.11665/j.issn.1000-5048.20140606
shu

Synthesis and antitumor activity of NO-releasing alkoxylbiphenyl derivatives

More Information
    Graphical Abstract
    • Abstract
  • A series of NO-releasing alkoxylbiphenyl derivatives( 4a - 4g )were designed and synthesized by coupling the carboxyl group of alkoxylbiphenyl with NO donor. Their antitumor activities were evaluated by MTT assay in HepG-2, Bel-7402, SMMC-7721, QGY-7701 and Bel-7404 cell lines. The results indicated that the target compounds exhibited significant inhibitory effects on the proliferation of tumor cells, especially on HepG-2 cells(IC50=1. 15-4. 34 μmol/L). Notably, the inhibitory effect of the target compounds on non-tumor liver LO2 cells was relatively weak(IC50=5. 00-8. 53 μmol/L)except compound 4f , suggesting that these compounds have selective inhibitory effects on tumor cells in vitro. Additionally, compound 4b could significantly inhibit the parental sensitive K562 and drug-resistant K562/A02 cell proliferation, and the IC50s were 1. 28 and 1. 32 μmol/L, respectively. Importantly, treatment with various concentrations of an NO scavanger significantly reduced the antitumor activity of compound 4b , suggesting that NO produced by compound 4b may play a significant role in inhi-biting the proliferation of K562 and K562/A02 cells.
    • FullText(HTML)
    • References (13)
  • [1]
    Hu W,Li Y,Zhang CZ.Enantioseparation of racemic anti-hepatitis new drug bicyclol with crystallization[J].Chin Chem Lett(中国化学快报),2005, 16(11):1 471-1 473.
    [2]
    Hung HY,Ohkoshi E,Goto M,et al.Antitumor agents.293.Nontoxic dimethyl-4,4′-dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-dicarboxylate(DDB)analogues chemosensitize multidrug-resistant cancer cells to clinical anticancer drugs[J].J Med Chem,2012, 55(11):5 413-5 424.
    [3]
    Sun H,Liu GT.Chemopreventive effect of bicyclol on malignant transformation of WB-F344 rat liver epithelial cells and its effect on related signal transduction in vitro[J].Cancer Lett,2006, 236(2):239-249.
    [4]
    Jin J,Sun H,Wei H,et al.The anti-hepatitis drug DDB chemosensitizes multidrug resistant cancer cells in vitro and in vivo by inhibiting P-gp and enhancing apoptosis[J].Invest New Drugs,2007, 25(2):95-105.
    [5]
    Cortier M, Leon L, Sassi N, et al. Nitric oxide is a promising enhancer for cancer therapy[J].Nitric Oxide(NO)Cancer,2010:253-263.
    [6]
    Donia M,Maksimovic-Ivanic D,Mijatovic S,et al.In vitro and in vivo anticancer action of saquinavir-NO,a novel nitric oxide-derivative of the protease inhibitor saquinavir,on hormone resistant prostate cancer cells[J].Cell Cycle,2011, 10(3):492-499.
    [7]
    Han C,Huang ZJ,Zheng C,et al.Novel hybrids of(phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer[J].J Med Chem,2013, 56(11):4 738-4 748.
    [8]
    Ling Y, Ye XL, Zhang ZZ, et al. Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid:synthesis and evaluation of antihepatocellular carcinoma activity[J].J Med Chem,2011, 54(9):3 251-3 259.
    [9]
    Huang ZJ,Zhang YH,Zhao L,et al.Synthesis and anti-human hepatocellular carcinoma activity of new nitric oxide-releasing glycosyl derivatives of oleanolic acid[J].Org Biomol Chem,2010, 8(3):632-639.
    [10]
    Chen L,Zhang Y,Kong X,et al.Design,synthesis,and antihepatocellular carcinoma activity of nitric oxide releasing derivatives of oleanolic acid[J].J Med Chem,2008, 51(15):4 834-4 838.
    [11]
    Fu J,Liu L,Huang Z,et al.Hybrid molecule from O2-(2,4-dinitrophenyl)diazeniumdiolate and oleanolic acid:a glutathione S-transferase pi-activated nitric oxide prodrug with selective anti-human hepatocellular carcinoma activity and improved stability[J].J Med Chem,2013, 56(11):4 641-4 655.
    [12]
    Hutchens S, Manevich Y, He L, et al. Cellular resistance to a nitric oxide releasing glutathione S-transferase P-activated prodrug,PABA/NO[J].Invest New Drug,2011, 29(5):719-729.
    [13]
    Huang Z,Fu J,Liu L,et al.Glycosylated diazeniumdiolate-based oleanolic acid derivatives:synthesis,in vitro and in vivo biological evaluation as anti-human hepatocellular carcinoma agents[J].Org Biomol Chem,2012, 10(19):3 882-3 891.
    • Related Articles

  • Related Articles

    [1]LI Xueyan, CHEN Na, JIANG Cheng. Research progress of KRAS inhibitors[J]. Journal of China Pharmaceutical University, 2024, 55(2): 257-269. DOI: 10.11665/j.issn.1000-5048.2024010801
    [2]YANG Wanwan, YE Fangyu, WU Yujia, WANG Haochen, ZHAO Li. Research progress of PARP inhibitors in cancers and their drug resistance[J]. Journal of China Pharmaceutical University, 2022, 53(5): 525-534. DOI: 10.11665/j.issn.1000-5048.20220503
    [3]YANG Qian, WANG Xiaojian. Research progress of sphingosine kinase 1 inhibitors[J]. Journal of China Pharmaceutical University, 2021, 52(6): 759-768. DOI: 10.11665/j.issn.1000-5048.20210615
    [4]ZHAN Kangning, QUAN Xu, HUANG Zhangjian, ZHAO Liwen. Research progress of protein arginine methyltransferase 5 inhibitors[J]. Journal of China Pharmaceutical University, 2021, 52(3): 371-378. DOI: 10.11665/j.issn.1000-5048.20210315
    [5]LI Zhiyan, LIU Jie, LI Bingyan, JIANG Cheng. Design, synthesis and evaluation of peptidomimetics targeting the polo-box domain of polo-like kinase 1[J]. Journal of China Pharmaceutical University, 2020, 51(3): 287-294. DOI: 10.11665/j.issn.1000-5048.20200305
    [6]LIANG Tingting, WANG Wenjie, HE Guangchao, HE Guangchao, XU Yungen. Research progress of ERK small molecule inhibitors[J]. Journal of China Pharmaceutical University, 2020, 51(3): 260-269. DOI: 10.11665/j.issn.1000-5048.20200302
    [7]SHI Jinyu, BAI Ying, PENG Kewen, ZHANG Wenhui, ZHU Qihua, XU Yungen. Research progress of PARP-1 inhibitors in combination with other drugs to overcome drug resistance[J]. Journal of China Pharmaceutical University, 2019, 50(5): 523-530. DOI: 10.11665/j.issn.1000-5048.20190503
    [8]WANG Tianshuai, YU Junjie, ZHANG Yan, ZENG Jinjin, CUI Jingxin. Advances in platinum-intercalators of DNA as antitumor agents[J]. Journal of China Pharmaceutical University, 2019, 50(5): 505-515. DOI: 10.11665/j.issn.1000-5048.20190501
    [9]GUO Yahui, LU Peng, WANG Yubin, ZHANG Huibin. Progress in the researches for antitumor NEDD8 activating enzyme inhibitors[J]. Journal of China Pharmaceutical University, 2017, 48(6): 646-653. DOI: 10.11665/j.issn.1000-5048.20170603
    [10]KONG Kai-lai, LU Shuai, GAO Yi-ping, YANG Pei, TANG Wei-fang, LU Tao. Advances on the study of PLK1 inhibitors as antitumor agents[J]. Journal of China Pharmaceutical University, 2011, 42(1): 9-15.

Catalog

    Get Citation
    PDF
    XML
    Article views (1364) PDF downloads (1171) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：302646

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return